Literature DB >> 143928

Cerebrospinal fluid gamma-aminobutyric acid variations in neurological disorders.

S J Enna, L Z Stern, G J Wastek, H I Yamamura.   

Abstract

Neuropathologically, Huntington's disease is characterized by a profound reduction in neuronal cells originating in the corpus striatum and globus pallidus. Since one of these cell types utilizes gamma-aminobutyric acid (GABA) as a neurotransmitter, it may be possible to differentially diagnose this disorder on the basis of the CSF content of this amino acid. In order to determine the validity of this hypothesis, cerebrospinal fluid GABA was analyzed, using a recently developed radioreceptor assay procedure and was found to be significantly reduced in patients diagnosed as having Huntington's disease and also lower in patients with Alzheimer's disease, though no difference was noted between Parkinson patients and control subjects. The results suggest that analysis of cerebrospinal fluid GABA may have diagnostic, and perhaps predictive, value in certain neurological disorders.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 143928     DOI: 10.1001/archneur.1977.00500230053008

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  17 in total

Review 1.  Clinical relevance of measuring GABA concentrations in cerebrospinal fluid.

Authors:  P J Schechter; A Sjoerdsma
Journal:  Neurochem Res       Date:  1990-04       Impact factor: 3.996

2.  Free-GABA levels in the cerebrospinal fluid of patients suffering from several neurological diseases Its potential use for the diagnosis of diseases which course with inflammation and tissular necrosis.

Authors:  A T Zepeda; F J Ortiz Nesme; J Méndez-Franco; E Otero-Siliceo; M Pérez de la Mora
Journal:  Amino Acids       Date:  1995-09       Impact factor: 3.520

3.  Increased GFAp levels in CSF as a marker of organicity in patients with Alzheimer's disease and other types of irreversible chronic organic brain syndrome.

Authors:  R Crols; J Saerens; M Noppe; A Lowenthal
Journal:  J Neurol       Date:  1986-06       Impact factor: 4.849

Review 4.  Neurotransmitter replacement therapy in Alzheimer's disease.

Authors:  E Mohr; T Mendis; I N Rusk; J D Grimes
Journal:  J Psychiatry Neurosci       Date:  1994-01       Impact factor: 6.186

Review 5.  The current state of research with peripheral tissues in Huntington disease.

Authors:  G C Beverstock
Journal:  Hum Genet       Date:  1984       Impact factor: 4.132

Review 6.  Alterations of central GABAergic activity in neurologic and psychiatric disorders: evaluation through measurements of GABA and GAD activity in cerebrospinal fluid.

Authors:  T A Hare
Journal:  Mol Cell Biochem       Date:  1981-09-25       Impact factor: 3.396

Review 7.  Physiological and behavioral studies with muscimol.

Authors:  F V DeFeudis
Journal:  Neurochem Res       Date:  1980-10       Impact factor: 3.996

8.  Plasma and cerebrospinal fluid gamma-aminobutyric acid in neurological disorders.

Authors:  D Schmidt; W Löscher
Journal:  J Neurol Neurosurg Psychiatry       Date:  1982-10       Impact factor: 10.154

9.  Low CSF GABA concentration in children with febrile convulsions, untreated epilepsy, and meningitis.

Authors:  D Rating; H Siemes; W Löscher
Journal:  J Neurol       Date:  1983       Impact factor: 4.849

10.  GABAergic modulation of memory with regard to passive avoidance and conditioned suppression task in mice.

Authors:  T Nabeshima; Y Noda; T Kameyama
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.